The cannabinoid agonist market is gaining momentum due to expanding medical cannabis legalization and growing clinical validation for its use in chronic pain, epilepsy, and inflammatory conditions.

In the first placebo-controlled study of vaporized cannabis for acute migraine, patients report greater relief from pain and ...

Skye’s Nimacimab shows promise in obesity treatment with lean mass preservation. Phase 2a results slated for 2025 could drive ...

As patients increasingly turn to cannabis for chronic pain, clinicians grapple with mixed evidence and a lack of high-quality ...

Whilst limited, early research shows Cannabinol may offer promising benefits. Explore what CBN is, how it interacts with your body and potential health benefits.

MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIAMI, FLORIDA / ACCESS Newswire / ...

Nagging aches grow numb, sense of time slips away, colors brighten and thoughts grow crisp. Afterward, runners say they feel ...

But overall, our findings suggest cannabinoids may acutely influence sleep, primarily by suppressing REM sleep, without ...

Testing a cannabinoid drug in disease models. The study explored the impact of WIN55.212-2, a synthetic compound targeting cannabinoid receptors, in rodent models mimicking early stages of ...

Ménard and colleagues described their studies in Nature Neuroscience, in a paper titled, “Astrocytic cannabinoid receptor 1 promotes resilience by dampening stress-induced blood-brain barrier ...